President/CEO
Skye Bioscience
Skye Bioscience is a biopharmaceutical company developing first-in-class monoclonal antibodies that inhibit the peripheral CB1 receptor to promote sustainable weight loss and improve metabolic health. Their lead candidate, nimacimab, aims to enhance drug tolerability and patient adherence with potential dosing intervals of once a week to once a month.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- Skye Bioscience is a biopharmaceutical company developing first-in-class monoclonal antibodies that inhibit the peripheral CB1 receptor to promote sustainable weight loss and improve metabolic health. Their lead candidate, nimacimab, aims to enhance drug tolerability and patient adherence with potential dosing intervals of once a week to once a month.